# Clene Inc. (CLNN) · Edgar & Edgarette company card

> Clene (CLNN) saw revenue fall 41.5% in FY2025 to $0 million, operating margin -11541% against a -3.8% median for pharmaceutical preparations, equity -97.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1822791 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CLNN) · [JSON](https://www.pops4.com/boards/company/CLNN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $200,000 |
| Revenue growth, 1 year | -41.5% |
| Revenue growth per year | -27.5% |
| Operating margin | -11541.5% (prior year -9676.3%) |
| Net margin | -13086.5% |
| Operating cash flow | −$19M |
| Capital spending | $39,000 |
| Free cash flow | −$19M |
| Cash | $5M |
| Long-term debt | $18M |
| Total assets | $18M |
| Total equity | −$18M |
| Equity ÷ assets | -97.0% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -65.16 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$18.5M in FY2025); operating loss: a margin of -11541.5% in FY2025; revenue is hard to predict: its 80% range is ±85%

## Edgarette's reading

Exposure: revenue $200K (FY2025), total debt $17.8M. Experience: revenue down 41.5% on the year, down 27.5% a year over 4 years; operating margin -11541.5%, down from -9676.3%. Soundness: equity -97.0% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $38K and $460K next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $32K to $548K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -11541.5% against a -3.8% median; growth -41.5% against 13.7%.

Range logged 2026-09-24, receipt 36233a3527076b49, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-05-22 ([filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926018267/0001437749-26-018267-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926034776/0001437749-26-034776-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926034775/0001437749-26-034775-index.htm)
- 8-K · filed 2026-10-20 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/0001437749-26-032960-index.htm)
- 8-K · filed 2026-10-19 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/0001437749-26-032882-index.htm)
- 8-K · filed 2026-09-16 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030581/0001437749-26-030581-index.htm)
- 8-K · filed 2026-08-14 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/0001437749-26-027837-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001822791.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1822791

## Cite

POPS4, Edgar & Edgarette: Clene Inc. (CLNN) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CLNN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.